Key features and details | |
Cat. No. | MABL-874 |
Name | Anti-CD30 mAbs |
Clone No. | AFD- Ki-3 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | Activate, ELISA, FC, IF, IHC |
Species Reactivity | Human |
Basic Information | |
Specificity | The antibody binds to CD30. |
Alternative Name | TNFRSF8; Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30 |
UniProt | P28908 |
Immunogen | Human CD30. |
Application Notes | The antibody binds specifically to CD30, a cell membrane protein which belongs to the tumour necrosis factor receptor family. Incubation of CD30 positive L540 cells with Ki-3 antibody weakly enhances release of soluble CD30 (in contrast to Ki-4, Ab00475). CD30 is expressed on activated lymphocytes, and binding by its ligands TRAF2 and TRAF5 results in the activation of NF-kappaB, thereby regulating gene expression. CD30 is also associated with Hodgkin Lymphoma, and its expression acts as a tumour marker. Targeting the CD30 antigen with specific monoclonal antibodies is a possible therapy for Hodgkin's lymphoma. |
Antibody First Published | Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 1995 Feb 8;60(4)：539-44.PMID：7530238 |
Note on publication | Describes the role of CD30 in the detection of Hodgkin lymphoma, and the production of monoclonal antibodies to inhibit the formation of soluble CD30 and thereby allow the production of immunotoxins. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
